Proposed changes to the National Institutes of Health (NIH) grant review and funding processes, spearheaded by the Office of Management and Budget (OMB), are generating significant concern among leading researchers and patient advocates. These revisions, outlined in a recent OMB proposal, threaten to politicize scientific inquiry, undermine decades of established research practices, and potentially stifle crucial advancements in medicine and public health, particularly in fields like geriatrics and palliative care.<\/p>\n
Background: The Pillars of NIH Funding<\/strong><\/p>\n For decades, the NIH has served as the primary engine for biomedical research funding in the United States. Its mission, to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and lessen the burden of illness and disability, has been guided by principles of scientific merit, peer review, and the pursuit of knowledge for the public good. The process typically involves rigorous peer review by panels of independent experts who evaluate the scientific quality, innovation, and potential impact of grant proposals. Funding decisions are then made based on these scientific assessments, with input from NIH scientific staff.<\/p>\n This established framework has been credited with numerous breakthroughs, from the development of life-saving vaccines and treatments for chronic diseases to a deeper understanding of aging and end-of-life care. However, recent proposals from the OMB suggest a significant departure from these foundational principles.<\/p>\n Key Proposed Revisions and Their Implications<\/strong><\/p>\n The OMB’s proposed changes introduce several critical shifts that have alarmed the scientific community:<\/p>\n Expert Reactions: A United Front of Concern<\/strong><\/p>\n Leading figures in geriatrics and palliative care have voiced strong opposition to these proposed changes, emphasizing their potential to undermine the very fabric of scientific progress.<\/p>\n Dr. Sean Morrison, Chair of the Department of Geriatrics and Palliative Medicine at the Icahn School of Medicine at Mount Sinai, articulated the core concern: "The Office of Management and Budget has proposed a number of changes in how grants are funded. First of all, grants need to match the policy of the executive government. The second is that traditionally it\u2019s been the best science that\u2019s been put forward for funding and that comes through review panels. Now that science is approved by a political appointee or it is proposed that it would be approved by a political appointee, there are significant restrictions on the type of research that can be funded."<\/p>\n Dr. Stacy Fischer, a geriatrician and palliative care researcher at the University of Colorado, highlighted the ethical implications: "If a clinical trial is stopped midway because it no longer aligns with the institution\u2019s priorities, that gift of their information, of their time that may be precious and limited is gone. It is wasted. It is, I think, really unethical and immoral to do that to people who have signed a consent as part of a clinical trial, expecting that their sacrifices and their gifts will not go to change practice or to help us understand something meaningful."<\/p>\n Dr. Ken Covinsky, a researcher at UCSF Division of Geriatrics, underscored the fundamental shift away from public trust: "The research enterprise, medical research, is a public trust. It exists to help our patients live better, free them of the burdens of disease. And so medical research exists for the needs of the public, for the needs of patients and their families. So now what this is saying is that after a medical research project has been vetted based on its impact on patients and families, a politician should decide if the medical research suits the interests of the current politicians in power."<\/p>\n Specific Areas of Contention<\/strong><\/p>\n Several specific aspects of the proposed revisions have drawn particular ire:<\/p>\n\n